Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APEX1 | P27695 | 1/20 | 0.55 |
| ▸ | F10 | P00742 | 2/20 | 0.51 |
| ▸ | F7 | P08709 | 2/20 | 0.51 |
| ▸ | F3 | P13726 | 2/20 | 0.51 |
| ▸ | F2 | P00734 | 1/20 | 0.51 |
| ▸ | C1R | P00736 | 6/20 | 0.50 |
| ▸ | KLK7 | P49862 | 5/20 | 0.47 |
| ▸ | KLK14 | Q9P0G3 | 5/20 | 0.47 |
| ▸ | KLK5 | Q9Y337 | 5/20 | 0.47 |
| ▸ | CTSG | P08311 | 4/20 | 0.47 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.47 |
| ▸ | ELANE | P08246 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL915773 | 0.81 | C1R (0.73) | APEX1F10F7F3F2 | |
| SCHEMBL914180 | 0.81 | APEX1 (0.56) | APEX1F10F7F3C1R | |
| SCHEMBL913737 | 0.79 | C1R (0.57) | APEX1F10F7F3F2 | |
| SCHEMBL914529 | 0.77 | APEX1 (0.65) | APEX1F7F3F2C1R | |
| SCHEMBL914380 | 0.74 | C1R (0.70) | APEX1C1RKLK7KLK14KLK5 | |
| SCHEMBL913631 | 0.74 | F7 (0.67) | APEX1F10F7F3F2 | |
| SCHEMBL4850801 | 0.74 | ELANE (0.66) | APEX1F2C1RELANEMEN1 | |
| SCHEMBL913679 | 0.72 | CTSG (0.51) | APEX1F10F7F3C1R | |
| SCHEMBL913650 | 0.72 | ELANE (0.77) | C1RELANE | |
| SCHEMBL915740 | 0.71 | APEX1 (1.00) | APEX1F10F7F3F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7872052-B2 | Use of heterocyclic compounds as SCCE inhibitors | AREXIS AB (SE) | 2011-01-18 | — | — | US | disclosed |
| US-20060258651-A1 | Use of heterocyclic compounds as scce inhibitors | QUANTUM LTO HOLDINGS, LLC | 2006-11-16 | — | — | US | disclosed |
| EP-1631295-A2 | USE OF FUSED HETEROCYCLIC COMPOUNDS AS SCCE INHIBITORS FOR THE TREATMENT OF SKIN CONDITIONS OR CANCER | Arexis AB (SE) | 2006-03-08 | — | — | EP | disclosed |
| WO-2004108139-A2 | USE OF FUSED HETEROCYCLIC COMPOUNDS AS SCCE INHIBITORS FOR THE TREATMENT OF SKIN CONDITIONS OR CANCER | AREXIS AB (SE) | 2004-12-16 | — | — | WO | disclosed |
| US-6180625-B1 | MODULATING AND NORMALIZING AN IMPAIRED HAEMOSTATIC BALANCE IN A MAMMAL, WHICH METHOD COMPRISES ADMINISTERING AN EFFECTIVE AMOUNT OF NOVEL BENZOXAZIN DERIVATIVES; ANTICOAGULANTS | NOVO NORDISK A/S (DK) | 2001-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258651-A1 | Use of heterocyclic compounds as scce inhibitors | RCE1, CTSE, SPINT2 | APEX1 1422/4885F10 937/4885F7 3152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.